secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2023-07-17T23:59:59+00:00
Accession:  0001193125-23-187702
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux reports ~$304M cash; JANX007 interim data show PSA drops 31-67% in 4/5 patients
--------------------------------------------------------------------------------

- Preliminary cash, equivalents, and short-term investments ~$304.1M as of June 30, 2023.
- JANX007 Phase 1a: 4 of 5 patients at flat doses (100-300µg) achieved PSA reductions of 31-67%.
- No dose-limiting toxicities; CRS Grade 1-2 only in patients with PSA reductions; no Grade 3 CRS.
- PK shows prolonged TRACTr exposure and lack of TCE accumulation, consistent with tumor activation.
- Development moving into step-dosing and dose optimization to enhance efficacy with manageable safety.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312523187702/0001193125-23-187702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312523187702/d526906d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-187702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer